Open

Immunotherapy study for patients with stage II-III breast cancer

We are studying and comparing two different treatments for stages II-III breast cancer to find out which is the more effective. In this study, we are comparing neoadjuvant chemotherapy alone with treatment with neoadjuvant chemotherapy PLUS an immunotherapy drug called durvalumab.

Age & Gender

18 years ~ 99 years
Male, Female

Visit Availability

Standard business hours (M-F, 8-5)

Location

North Carolina (Statewide)

What will be asked of you

At each visit, you will meet with a member of study team to review any side effects from treatment and at specific visits you will fill out questionnaires. The study also involves lab tests before each treatment and a mammogram annually if clinically necessary.

In-person visits:
33-35

Total length of participation:
11 years

Looking for Specific Volunteers

Able to participate:

You have Stage II or III Breast Cancer
MammaPrint MP2 result
hormone receptor positive breast cancer
HER2 negative breast cancer
Zubrod Performance Status of 0-2

Not eligible if:

You have Metastatic Breast Cancer
You have a history of (non-infectious) pneumonitis that required steroids or evidence of active pneumonitis within the past two year
You have active autoimmune disease that has required systemic treatment in the past two years.
You have uncontrolled diabetes, (Hemoglobin A1c of 9.0% or greater)

Contact the Team

Visit Location

Contact & Visit Location

Additional Study Information

Principal Investigator

Anureet Copeland
UNC Hospitals - Rex

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Breast)

IRB Number

23-2910

ClinicalTrials.gov

NCT06058377

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.